Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CNTB
CNTB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CNTB News
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact
Nov 13 2025
Benzinga
Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update
Nov 12 2025
Newsfilter
Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Oct 31 2025
Benzinga
BTIG Begins Coverage of Connect Biopharma Holdings with a Buy Rating and Sets Price Target at $10
Oct 31 2025
Benzinga
Connect Biopharma to Participate in Two Investor Conferences This September
Aug 27 2025
Newsfilter
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
Jul 30 2025
NASDAQ.COM
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Jul 22 2025
Newsfilter
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
Jul 18 2025
Newsfilter
Connect Biopharma Regains Nasdaq Compliance On Minimum Bid Price
Jul 17 2025
NASDAQ.COM
HC Wainwright & Co. Assumes Connect Biopharma Hldgs at Buy, Announces Price Target of $7
Jun 12 2025
Benzinga
Connect Biopharma Announces Significant Findings Regarding Rademikibart
May 20 2025
NASDAQ.COM
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
May 15 2025
Newsfilter
Connect Biopharma Posts Wider Loss In Q1
May 15 2025
NASDAQ.COM
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
May 14 2025
Newsfilter
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Apr 01 2025
Newsfilter
Show More News
